Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $6.1 up 1.16% from its previous closing price of $6.03. In other words, the price has increased by $1.16 from its previous closing price. On the day, 2.12 million shares were traded. DAWN stock price reached its highest trading level at $6.12 during the session, while it also had its lowest trading level at $5.8503.
Ratios:
For a deeper understanding of Day One Biopharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.65. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 16 ’25 when Merendino Lauren sold 3,927 shares for $6.26 per share. The transaction valued at 24,575 led to the insider holds 35,161 shares of the business.
Dubow Adam sold 4,552 shares of DAWN for $28,486 on May 16 ’25. The GENERAL COUNSEL now owns 47,136 shares after completing the transaction at $6.26 per share. On May 16 ’25, another insider, York Charles N II, who serves as the COO, CFO AND SECRETARY of the company, sold 4,282 shares for $6.26 each. As a result, the insider received 26,796 and left with 265,231 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 624835200 and an Enterprise Value of 174734784. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.33 while its Price-to-Book (P/B) ratio in mrq is 1.36. Its current Enterprise Value per Revenue stands at 0.931 whereas that against EBITDA is -1.606.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.26, which has changed by -0.5478132 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $16.76, while it has fallen to a 52-week low of $5.64. The 50-Day Moving Average of the stock is -8.79%, while the 200-Day Moving Average is calculated to be -37.52%.
Shares Statistics:
For the past three months, DAWN has traded an average of 1.57M shares per day and 2667700 over the past ten days. A total of 102.43M shares are outstanding, with a floating share count of 75.46M. Insiders hold about 26.33% of the company’s shares, while institutions hold 83.48% stake in the company. Shares short for DAWN as of 1752537600 were 10280741 with a Short Ratio of 6.57, compared to 1749772800 on 12608785. Therefore, it implies a Short% of Shares Outstanding of 10280741 and a Short% of Float of 15.09.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of Day One Biopharmaceuticals Inc (DAWN) in the stock market.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.18 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.8 and -$1.35 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$0.83, with 8.0 analysts recommending between -$0.4 and -$1.42.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $38.38M this quarter.It ranges from a high estimate of $41M to a low estimate of $36.75M. As of the current estimate, Day One Biopharmaceuticals Inc’s year-ago sales were $93.76MFor the next quarter, 8 analysts are estimating revenue of $41.62M. There is a high estimate of $47M for the next quarter, whereas the lowest estimate is $37.9M.
A total of 9 analysts have provided revenue estimates for DAWN’s current fiscal year. The highest revenue estimate was $151M, while the lowest revenue estimate was $139.32M, resulting in an average revenue estimate of $144.71M. In the same quarter a year ago, actual revenue was $131.16MBased on 9 analysts’ estimates, the company’s revenue will be $214.24M in the next fiscal year. The high estimate is $295M and the low estimate is $171.12M.